AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Consensus Target Price of $37.50 According to Brokerages

Key Points

• Analysts maintain a broadly positive view: AgomAb Therapeutics has a “Moderate Buy” consensus from nine analysts, with eight Buy ratings and one Hold. The average 12-month price target is $37.50, although targets vary significantly, including Piper Sandler’s $60 objective and a recent Sell downgrade from Wall Street Zen.
• Insiders have been buying shares: Executives and directors purchased 41,000 shares worth approximately $357,080 over the past quarter, including recent purchases by the CEO, CFO, and a director.
• The stock remains loss-making and under pressure: AGMB opened at $9.05, below its 50-day and 200-day moving averages, while analysts expect a full-year loss of roughly $1.77 per share. Its valuation depends heavily on progress in lead program AGMB-129 and other clinical-stage programs.

AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $37.50.

AGMB has been the subject of a number of recent research reports. Wall Street Zen downgraded AgomAb Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, September 27th. Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an "overweight" rating for the company. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a "buy" rating and a $34.00 price target on the stock. Piper Sandler initiated coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They set an "overweight" rating and a $60.00 price objective on the stock. Finally, Johnson Rice reissued a "buy" rating on shares of AgomAb Therapeutics in a research note on Wednesday.

More AgomAb Therapeutics News

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: Director David Epstein purchased 10,000 AGMB shares at an average price of $8.88, investing approximately $88,800 and increasing his direct ownership by 66.7% to 25,000 shares. Insider buying can signal management confidence that the stock is undervalued. AgomAb Therapeutics Director Buys 10,000 Shares
• Positive Sentiment: HC Wainwright raised its EPS forecasts for every year from fiscal 2026 through fiscal 2030. The revisions were modest but consistently favorable, with estimated losses narrowing to $1.91 per share in 2026, $2.02 in 2027, $1.75 in 2028, $1.81 in 2029 and $1.79 in 2030. The firm maintained its “Buy” rating.
• Neutral Sentiment: Analyst sentiment remains broadly constructive, with the company described as having a “Moderate Buy” consensus and several firms maintaining Buy or Overweight ratings. However, one research firm recently downgraded the shares to Sell, highlighting disagreement about the company’s outlook.
• Negative Sentiment: AgomAb is still expected to report losses, including a consensus estimate of approximately $1.83 in negative EPS for the current year. As a clinical-stage biotechnology company, its valuation remains dependent on progress in programs such as AGMB-129, while the shares continue to trade below their key moving averages.

Insiders Place Their Bets

In related news, CEO Tim Jasper Knotnerus purchased 5,000 shares of the firm's stock in a transaction dated Tuesday, October 6th. The stock was purchased at an average price of $8.70 per share, with a total value of $43,500.00. Following the completion of the purchase, the chief executive officer owned 21,823 shares of the company's stock, valued at approximately $189,860.10. The trade was a 29.72% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Pierre Kemula bought 10,000 shares of the stock in a transaction on Tuesday, October 6th. The stock was purchased at an average price of $8.59 per share, with a total value of $85,900.00. Following the completion of the acquisition, the chief financial officer directly owned 10,000 shares in the company, valued at approximately $85,900. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 41,000 shares of company stock worth $357,080 over the last quarter.

AgomAb Therapeutics Trading Down 2.3%

Shares of AgomAb Therapeutics stock opened at $9.05 on Friday. The firm's 50-day moving average is $11.52 and its 200 day moving average is $11.75. AgomAb Therapeutics has a 1 year low of $7.92 and a 1 year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. Equities analysts expect that AgomAb Therapeutics will post -1.77 EPS for the current year.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company's research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab's lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn's disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.